|
Market Cap (5-Jul) $86,511,600 (718th) |
Close (30-Jun) $0.63 |
Volume (30-Jun) 55,179 |
Shortsold (19-Jun) 190,561 (0.07%) (455th) |
|
52w High $0.57 |
52w Low $0.275 |
P/E - |
EPS -0.09 |
RCE released this announcement to the ASX on 18 January 2022, 13:23. The announcement is marked as price sensitive, and is 3 page(s) in length and 267.69kb in size.
You can view all announcements from RCE and see how they appear on a price chart on the announcements page.
At the date of this announcement, RCE was 0.228% short sold according to ASIC data. It was ranked the 386th most shorted stock on the ASX. It remains ranked 455th as of the latest reported data (19 June 2025).
| Other Recent Announcements from RCE | |
|---|---|
| Ethics Approval for Phase I/II UTI Trial Expansion | 29 June 2023, 13:49 |
| Change of Director's Interest Notice - J Graham | 26 June 2023, 15:58 |
| DFI Clinical Trial Outpatient Nurses Appointed | 29 May 2023, 10:54 |
| Positive Safety Data from Second Cohort of PI Clinical Trial | 18 January 2022, 13:23 |
| Positive Safety Data from Phase 1 Clinical Trial | 7 January 2022, 10:31 |
| Patients to be Dosed in Ph 1 IV Clinical Trial of R327 | 15 December 2021, 9:24 |
| Update on Phase I/II Clinical Trial for Burn Wound Infection | 7 December 2021, 9:43 |
You must be logged in to post a reply.
Recce Pharmaceuticals Ltd 